Reply  by Grisafi, Joseph L. et al.
LETTERS TO THE EDITOR
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fRegarding “Endoluminal treatment of type IA
endoleak with Onyx”
We read with great interest the article by Grisafi et al1 recently
published in the Journal of Vascular Surgery that reported effec-
tiveness of selective arterial embolization using Onyx in a patient
with type IA endoleak after endovascular abdominal aortic aneu-
rysm repair. We have several comments. First of all, we would like
to congratulate the authors for their case, which represents the first
one to date reporting results on transarterial embolotherapy with
Onyx as an embolic agent in such a setting. However, the only
available data on the use of this embolic material for peripheral
applications come from case reports. Indeed, Onyx is a new liquid
embolic agent composed of ethylene-vinyl alcohol copolymer dis-
solved in dimethyl sulphoxide (DMSO), with emerging applica-
tions in neurovascular procedures, predominantly embolization of
cerebral aneurysms and arteriovenous malformations.2 The main
advantages of Onyx are its nonadhesive properties, high radiopac-
ity, and long solidification periods, which, compared with acrylic
glues, make the embolization procedure more controllable and
predictable.3 Nevertheless, the authors did not bring to attention
in detail several important disadvantageous characteristics of the
use of Onyx. First, DMSO can cause severe vasospasm if injected
rapidly. This is most likely to occur early in the procedure and can
be avoided by using no more than 0.2 mL of DMSO in the first
minute of injection. In this case, the authors used a total of six vials
of Onyx, but did not report the total injection time of DMSO and
Onyx for their procedure. In our experience, the duration of
injection can be time-consuming and varies depending on the
amount of Onyx used. Secondly, DMSO is volatile and is excreted
via respiration and sweat. This has a typical smell not unlike that of
diabetic ketoacidosis and may last a few days. The patient and ward
staff should be warned to expect this. Lastly, the use of Onyx has
cost implications, as it is much more expensive than alternative
embolic materials, and it requires specific DMSO-compatible mi-
crocatheters. The prohibitive costs of using Onyx have led to its
restricted use in neuroradiology in most of the institutions
around the world. Then, we suggest an alternative conservative
therapeutic option when correction of the type IA endoleak by
securing the attachment site with balloon angioplasty or stent
graft extension is impossible or unsuccessful,4 especially because
of the proximity of visceral arteries ostia. Indeed, selective
transarterial catheterization of the endoleak throughout proxi-
mal uncovered meshes of the stent and release of detachable
microcoils into the nidus can be successfully attempted, as we
recently reported.5 The remodeling technique using an intra-
aortic balloon catheter, initially developed for the treatment of
wide-necked intracranial aneurysms,6 is then needed in order to
stabilize the microcatheter and allow precise and safe deposition
of the microcoils against the aneurysmal wall, limiting the risk of
malposition or migration.5
In conclusion, we think the use of Onyx as an embolic agent is
very promising, but the important cost aspect needs to be borne in
mind when there are other cheaper alternatives that would be as
effective.
Romaric Loffroy, MD, PhD
Russell H. Morgan Department of Radiology and
Radiological Science
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Johns Hopkins Hospital
Baltimore, Md trric Steinmetz, MD, PhD
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We would like to thank Loffroy and Steinmetz for sharing
heir thoughts about the use of Onyx in the treatment of type IA
ndoleaks after endovascular aneurysm repair. They point out
everal key disadvantages of this embolic agent, and we agree with
heir characterization. As such, we inform all patients of the
haracteristic smell associated with the elimination of dimethyl
ulfoxide prior to treatment. This side effect is remarkably well
olerated, and we have received few complaints.
The potential for vasospasm is also well recognized. This
erves to emphasize the need for appropriate training of practi-
ioners in the use of this product. While vasospasm is of particular
oncern in the cerebrovasculature, our experience with treating en-
oleaks after endovascular aneurysm repair suggests the occurrence to
e infrequent. Our belief is that accurate placement of the microcath-
ter delivery system at the nidus in the aneurysm neck is important in
reventing vasospasm. As a result, we have avoided protracted injec-
ion times.
The cost implications of the agent may be high; however, this
hould be balanced against the cost of management of a ruptured
bdominal aortic aneurysm. Loffroy and Steinmetz suggest the
emodeling technique as a cost-effective alternative, yet the ex-
ense of this technique is not trivial. Further, coils may prove
isadvantageous when delivery to inaccessible endoleak outflow
hannels is desired. With Onyx, flow dynamics may be exploited to
each these targets.
The population of patients with type IA endoleaks at high risk
or open conversion is gratifyingly small. Unfortunately, our ability
o determine the optimal treatment strategy is hampered as a
esult. More study is needed to determine which endovascular
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April 20111164 Letters to the Editorinterventions are likely to be most effective in this challenging
setting.
Joseph L. Grisafi, MD
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Interventional Radiology
Allegheny General Hospital
Pittsburgh, Pa
doi:10.1016/j.jvs.2010.10.097
Regarding “An analysis of relationship between
quality of life indices and clinical improvement
following intervention in patients with intermittent
claudication due to femoropopliteal disease”
We would like to complement Dr Mazari et al1 for their strict
follow-up and large sample size in their study of correlation be-
tween quality of life (QoL) instruments and clinical improvement
following intervention in patients with intermittent claudication
(IC) due to superficial femoral artery disease.
The study was presented as a prospective observational study
of patients recruited from an ongoing randomized controlled trial
(RCT) comparing supervised exercise, angioplasty, and combined
therapy with data reported until 12 months after the intervention.
To our surprise, this manuscript referred to the exact same
group of 178 patients as mentioned in their article published
previously this year, on the 1-month and 3-month follow-up of
clinical and QoL outcomes of their well performed RCT compar-
ing the three interventions.2
Although the current article includes the 12-month follow-up
assessments, it does not show us the results of the clinical and QoL
outcomes by allocated intervention, which is much more relevant
for clinical practice.
This is a missed opportunity because long-term follow-up in a
large group of patients with IC randomized in three different inter-
ventions has not been performed before, the studies in this field are
scarce and we would actually like to know what the most optimal
treatment strategy is for a patient with IC. Also, because only one
former publication focused on patients with IC due solely to femoro-
popliteal artery disease (comparing two interventions; supervised ex-
ercise with combined therapy) and they were unable to give a clear
answer owing to low recruitment rate and low rate of eligibility.3
In conclusion, QoL index scores are evidently an appropriate
tool for independent outcome reporting following interventions
for IC, but we do not see the newsworthiness of reporting QoL
changes after all interventions together. Despite our comment, we
certainly look forward to the long-term results of this study initi-
ated by the Academic Vascular Surgery Unit of the University of
Hull (http://ClinicalTrials.gov identifier: NCT00798850).
Franceline Alkine Frans, MD
Department of Radiology and Vascular Surgery
Academic Medical Center
Amsterdam, The Netherlands
Mark J. W. Koelemay, MD, PhD
Department of Vascular Surgery
Academic Medical Center
Amsterdam, The Netherlands
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We appreciate and welcome the comments made by Dr Frans
nd Dr Koelemay regarding our article and would like to address
he issues they raised, one by one:
First, we clearly mentioned in the Methods section that this
as an observational study that recruited patients from an ongoing
andomized controlled trial (RCT). This is the largest RCT to date
n claudicant patients with femoropopliteal disease and has many
ubsidiary studies running alongside. Because the study under
onsideration was purely observational, no sample size calculations
ere performed, and we aimed to maximize the recruitment to get
eliable and robust results. In this particular instance, all trial
articipants consented to take part in the study and were included
n the final analysis.
Second, there is a dearth of studies reporting the relationship
etween quality-of-life (QOL) indexes and clinical indicators, as
entioned in the introduction and in the Discussion section.
ecause these indexes are commonly used in economic analyses, it
s important to study and establish their relationship, and the study
as conducted to answer this specific question in all treatment
roups. Therefore, subgroup analysis was not performed as a part
f this study. Furthermore, subgroup analysis of QOL indicators is
ncluded in the results of the RCT and, therefore, cannot be
resented in this particular article.
Third, the findings of this study provide evidence to use
omposite outcome measures, including clinical and QOL indica-
ors in future studies, regardless of the treatments. This, in our
iew, was worthy of reporting to the scientific community. This
iew was clearly shared by our peers who reviewed the manuscript
nd found it worthy of publication in this esteemed journal.
And finally, the final results of the RCT are currently under
eview for publication, and we hope that they will provide the
nswers that Dr Frans and Dr Koelemay are looking for.
ayyaz Ali Khan Mazari, MBBS, MRCS
an C. Chetter, MBChB, FRCS
on behalf of all the authors)
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niversity of Hull
ast Yorkshire, United Kingdom
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he Swedish experience of screening for abdominal
ortic aneurysm
Ruptured abdominal aortic aneurysm (AAA) is a common
ause of death among elderly men. Early detection by screening
ith ultrasound and prophylactic surgery in appropriately selected
